Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
OptioRx
AddedFeb 15, 2024
UpdatedJun 18, 2026
OptioRx

OptioRx

Series B

Optio Rx, a US-licensed provider of specialty compounding pharmacies and home infusion services.

HQ
Oak Brook, IL, US
Founded
2018
Overview
Compare
Fundraising
Employees
Website

Founded with a mission to enhance patient care through specialized pharmaceutical services, Optio Rx operates as a premier national provider of specialty compounding pharmacies and home infusion services. The company focuses on delivering customized medications for both human and veterinary patients, addressing unique therapeutic needs that standard medications cannot meet. Licensed across the United States, Optio Rx offers a range of specialized therapies, including Bioidentical Hormone Replacement Therapy (BHRT) and Low Dose Naltrexone, ensuring nationwide convenience and speed to therapy.

Optio Rx has garnered attention for its commitment to quality and patient care, earning accreditations that underscore its reliability and excellence in the pharmaceutical industry. The company collaborates with a network of healthcare providers to ensure seamless service delivery. Notable investors and affiliated individuals have supported Optio Rx's growth, contributing to its reputation as a trusted partner for both patients and healthcare providers. Through its innovative approach and dedicated service, Optio Rx has significantly impacted the specialty pharmacy sector, improving health outcomes for diverse patient populations.

OptioRx - Quick Facts

When was OptioRx founded?

OptioRx was founded in 2018.

Where is OptioRx's headquarters located?

OptioRx's headquarters is located in Oak Brook, IL, US.

When was OptioRx's last funding round?

OptioRx's most recent funding round was for $27.3M (USD) in July 2018.

How much has OptioRx raised to-date?

As of Jul 23, 2018, OptioRx has raised a total of $27.3M (USD).

How many employees does OptioRx have?

OptioRx has 350 employees as of Feb 5, 2024.

OptioRx - Classification

Industry
  • Retail
Technology
  • Telemedicine
Geographic Exposure
  • United States
Revenue
  • Transactional
Customer
  • Consumers
Main Product
  • Infusion
  • Pharmacy
Tags
  • Healthtech
NAICS
  • 620000Health Care and Social Assistance
SIC
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified
Show 15 more industry codes
NAICS
  • 320000Manufacturing
  • 325400Pharmaceutical and Medicine Manufacturing
  • 456000Health and Personal Care Retailers
  • 450000Retail Trade
  • 325000Chemical Manufacturing
  • 623000Nursing and Residential Care Facilities
  • 456100Health and Personal Care Retailers
  • 325410Pharmaceutical and Medicine Manufacturing
  • 456110Pharmacies and Drug Retailers
  • 325412Pharmaceutical Preparation Manufacturing
SIC
  • 2800Chemicals And Allied Products
  • 5900Miscellaneous Retail
  • 2830Drugs
  • 5910Drug Stores And Proprietary Stores
  • 2834Pharmaceutical Preparations